---
figid: PMC6835115__tlcr-08-05-667-f3
figtitle: Targeting PKCι-PAK1 in EGFR-mutation positive non-small cell lung cancer
organisms:
- Homo sapiens
pmcid: PMC6835115
filename: tlcr-08-05-667-f3.jpg
figlink: /pmc/articles/PMC6835115/figure/f3/
number: F3
caption: Our model. PAK1 activates the PI3K/AKT signaling pathway and PKCι activates
  PAK1 through Ect2 and RAC1. Auranofin with IPA-3 (liposomal formulation), or other
  PAK inhibitors, could become a therapeutic solution for EGFR-mutation positive NSCLC
  patients resistant to EGFR TKIs.
papertitle: Targeting PKCι-PAK1 in EGFR-mutation positive non-small cell lung cancer.
reftext: Masaoki Ito, et al. Transl Lung Cancer Res. 2019 Oct;8(5):667-673.
year: '2019'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9343274
figid_alias: PMC6835115__F3
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC6835115__F3
ndex: 272eea65-de99-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6835115__tlcr-08-05-667-f3.html
  '@type': Dataset
  description: Our model. PAK1 activates the PI3K/AKT signaling pathway and PKCι activates
    PAK1 through Ect2 and RAC1. Auranofin with IPA-3 (liposomal formulation), or other
    PAK inhibitors, could become a therapeutic solution for EGFR-mutation positive
    NSCLC patients resistant to EGFR TKIs.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - AXL
  - EGFR
  - CDCP1
  - AKT1
  - AKT2
  - AKT3
  - KRAS
  - HRAS
  - NRAS
  - JAK2
  - SRC
  - FGR
  - FYN
  - YES1
  - RAC1
  - RNASE1
  - PAK1
  - PKN1
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - STAT3
  - ECT2
  - EPHB2
  - MAPK1
  - MAPK3
  - YAP1
  - PRKCI
  - PC
  - IPA
  - auranofin
  - Cancer
  - Lung cancer
---
